ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
uniQure NV

uniQure NV (QURE)

6.73
-0.93
(-12.14%)
終値: 11月13日 6:00AM
7.17
0.44
( 6.54% )
取引時間後: 8:43AM

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

通貨
7.17
買値
6.80
売値
7.21
出来高
989,758
6.51 日の範囲 7.505
3.73 52 週間の範囲 11.35
時価総額
前日終値
7.66
始値
7.48
最終取引時間
財務取引量
US$ 6,981,661
VWAP
7.0539
平均取引量 (3 か月)
658,636
発行済株式数
48,743,140
配当利回り
-
PER
-1.06
1 株当たり利益 (EPS)
-6.33
歳入
21.9M
純利益
-308.48M

uniQure NV について

uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipel... uniQure NV is a gene therapy company. It develops treatment and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Amsterdam, North Holland, Nld
設立
-
uniQure NV is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker QURE. The last closing price for uniQure NV was US$7.66. Over the last year, uniQure NV shares have traded in a share price range of US$ 3.73 to US$ 11.35.

uniQure NV currently has 48,743,140 shares in issue. The market capitalisation of uniQure NV is US$373.37 million. uniQure NV has a price to earnings ratio (PE ratio) of -1.06.

QURE 最新ニュース

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

~ Type B meeting scheduled with the FDA in the fourth quarter of 2024 to initiate discussions regarding a potential expedited clinical development pathway for AMT-130 in Huntington’s disease ~ ~...

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

LEXINGTON, Mass. and AMSTERDAM, Oct. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

LEXINGTON, Mass. and AMSTERDAM, Sept. 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
11.7231.55963302755.457.965.3510202437.28783362CS
41.5327.12765957455.647.965.357404586.6500069CS
120.598.966565349546.587.964.456586365.96179016CS
262.2445.43610547674.9311.353.7317675137.69065319CS
521.1619.30116472556.0111.353.7313958977.07138691CS
156-25.85-78.28588734133.0233.033.7396033411.83114873CS
260-46.62-86.670384829953.7976.68693.7376866320.05929658CS

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
BTCTBTC Digital Ltd
US$ 10.50
(316.67%)
128.41M
NANano Labs Ltd
US$ 8.03
(144.07%)
1.49M
NXTTNext Technology Holding Inc
US$ 2.0374
(77.16%)
5.54M
MULNMullen Automotive Inc
US$ 2.95
(72.51%)
65.56M
PAMTPAMT Corporation
 21.54
(70.82%)
68.88k
ACABAtlantic Coastal Acquisition Corporation II
US$ 5.77
(-47.06%)
162.29k
NGNENeurogene Inc
US$ 39.875
(-44.25%)
1.99M
RMTIRockwell Medical Inc
US$ 2.84
(-38.92%)
6.48M
PROCProcaps Group SA
US$ 0.97
(-37.33%)
100.99k
STIMNeuronetics Inc
US$ 0.6999
(-36.37%)
7.77M
CEROCERo Therapeutics Holdings Inc
US$ 0.2711
(38.32%)
769.95M
LGMKLogicMark Inc
US$ 0.184
(38.35%)
548.63M
NVDANVIDIA Corporation
US$ 148.29
(2.09%)
198.47M
LIFWMSP Recovery Inc
US$ 0.1144
(-9.71%)
170.3M
TSLATesla Inc
US$ 328.49
(-6.15%)
155.31M